Skip to content
15% off your first order15% off your first order

Thymosin Alpha-1 10 mg vial

Immune support

Investigated for T-cell maturation and immune balance.

$109.00CAD· $10.90/mg
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Needles and wipes are free. Water is $19.

Compare. Side by side, from the research.

About Thymosin Alpha-1

Thymosin Alpha-1 is a peptide originally isolated from thymic tissue. Research examines its role in the maturation of T-cells and in coordinating a balanced immune response.

How it works

T-Cell Maturation
Studied for its influence on the development and differentiation of T-cells within adaptive immunity.
Receptor Signaling
Explored for activity at toll-like receptors that sit early in the immune recognition cascade.
Read the full research

What you need

  • Bacteriostatic Water
  • Needles
  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Lyophilised powder in a sealed vial
Strength
10 mg per vial
Storage
Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
Reconstitution
2 mL bacteriostatic water for this 10 mg vial (5 mg/mL)
Route in research
Subcutaneous
SKU
TA10

Handling

  1. 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
  2. 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
  3. 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Early clinical

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

Early clinicalThymosin Alpha-1 has been examined in human research, including a multicenter cohort study in COVID-19 and clinical work in chronic hepatitis B, alongside animal and cell studies of its immune effects.

What research examines

  • T-cell maturation and differentiation
  • Toll-like receptor signaling on dendritic cells
  • NK-cell activity in immunosuppressed mouse models
  • Chronic hepatitis B research
  • COVID-19 in a multicenter cohort study
  • Immunoregulation in cancer and immuno-oncology research

Reported in studies

  • Human safety data in the cited literature are limited
  • Adverse events are not summarized in the cited studies
  • A 1996 laboratory study reported that Thymosin Alpha-1 did not promote growth or oncogenic transformation
  • Cell studies reported no effect on F508del-CFTR maturation or activity
Read the full research page· 5 cited studies

Published research protocols

1.5 mg, 3x/week, am

Research protocols have used 1.5–3 mg per administration, 3 times per week (morning), in 8-week blocks with 4 weeks off.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

Measure with the calculator

CoreX AI

Ask about Thymosin Alpha-1

Plain answers, from the basics to the studies.

Research information, not medical advice.

Often researched with Thymosin Alpha-1

Researched for immune support.

Shop Immune support

FAQ

Questions, answered

  • Thymosin Alpha-1 is a peptide originally isolated from thymic tissue. Research has examined its role in the maturation of T-cells and in coordinating a balanced immune response. It is broadly associated with immune signaling and has been studied for effects on both T-lymphocytes and natural killer (NK) cells. It has been the subject of reviews, animal studies, and human research spanning several decades.

  • Research investigates Thymosin Alpha-1 for activity at toll-like receptors on dendritic cells, which sit early in the immune recognition cascade. This upstream signaling is thought to relate to the T-cell differentiation it is most associated with. It has also been studied for its influence on the development and differentiation of T-cells within adaptive immunity. The full mechanism remains an active area of investigation.

  • Research has covered several areas. A 1983 mouse study reported restored NK-cell activity and reduced tumor progression in animals immunosuppressed by cytostatics or X-rays. Human research includes chronic hepatitis B and a multicenter cohort study in COVID-19. Reviews have discussed its immunoregulatory potential in cancer and immuno-oncology, and its relationship to aging. Cystic fibrosis cell studies reported no correction of F508del-CFTR.

  • Human safety data in the cited literature are limited, and adverse events are not summarized in the cited studies. A 1996 laboratory study reported that Thymosin Alpha-1 did not promote growth or oncogenic transformation. Separate cell studies found it did not influence F508del-CFTR maturation or activity, which is a negative efficacy finding rather than a safety signal. Further controlled research would be needed to characterize its safety profile fully.

  • Research protocols have used 1.5–3 mg per administration by the subcutaneous route, 3 times per week in the morning, in 8-week blocks followed by 4 weeks off. These figures describe what has appeared in research protocols and are not recommendations. Each CoreX order ships with a protocol guide for laboratory reference. CoreX supplies Thymosin Alpha-1 for laboratory research use only.